Key takeaways
Stelara (ustekinumab) and Remicade (infliximab) are both injectable biologic medications that treat autoimmune conditions such as Crohn's disease and ulcerative colitis. They each block different proteins involved in inflammation: Stelara blocks interleukins IL-12 and IL-23, while Remicade blocks tumor necrosis factor (TNF). Stelara is also approved for plaque psoriasis and psoriatic arthritis, whereas Remicade is approved for rheumatoid arthritis, ankylosing spondylitis, and severe plaque psoriasis. Stelara is typically given as an injection under the skin every 8 to 12 weeks, while Remicade is administered through an IV infusion every 6 to 8 weeks. Stelara and Remicade both have lower-cost biosimilars available. Common side effects of Stelara include cold symptoms and headaches, while Remicade can cause infusion-related reactions and infections. Both medications can weaken your immune system, so you should avoid live vaccines while taking them.
